The societal economic burden of autosomal dominant polycystic kidney disease in the United States
BMC Health Services Research
An Analysis Group team collaborated on the first study of the direct and indirect costs of autosomal dominant polycystic kidney disease (ADPKD) in the US. In the article “The societal economic burden of autosomal dominant polycystic kidney disease in the United States,” published in BMC Health Services Research, the team estimates total annual costs attributed to this inherited kidney disease in the US to be between $7.3 billion and $9.6 billion, equivalent to between $51,970 and $68,091 per individual with ADPKD. The authors found that the largest part of the economic burden was attributed to direct health care costs, which are incurred predominantly by public and private health care payers.
The study, which was conducted in collaboration with Otsuka Pharmaceutical Development & Commercialization, Inc., was written by a team including Analysis Group Managing Principal Annie Guerin, Vice President Martin Cloutier, and Manager Marjolaine Gauthier-Loiselle.
ADPKD is the fourth-leading cause of end-stage renal disease in the US. It is characterized by progressive development of renal cysts and numerous extra-renal manifestations, eventually leading to kidney failure. ADPKD is an especially challenging disease to treat because it can remain asymptomatic for years, which may result in delayed diagnosis and treatment. This study provides a clearer picture of the economic burden of the disease.